JANX News and Press, Janux Therapeutics Inc. From 05/07/24

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $651.8 million in cash and cash equivalents and short-term...

2024-05-02 16:09:01 ET More on Janux Therapeutics Janux Therapeutics: A Prime Target In Cancer Care's M&A Game Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux Therapeutics jump...

2024-05-02 10:03:17 ET Summary BioAtla is a biotech company focused on developing conditionally activated biologics for cancer therapy. Their approach is an attempt to harness the Warburg effect to conditionally activate immunological molecules. BioAtla has promising pipeline ...

2024-04-30 00:06:00 ET Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.4...

A look at the top 10 most actives in the United States Tesla Inc. (TSLA) rose 15.3% to $194.05 on volume of 241,483,966 shares SiNtx Technologies Inc. (SINT) rose 34.9% to $0.0545 on volume of 171,893,463 shares Collective Audience Inc. (CAUD) rose 61.6% to $0.6301 on volume of 156,906,40...

2024-04-29 15:49:56 ET More on Janux Therapeutics Janux Therapeutics: A Prime Target In Cancer Care's M&A Game Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux a new buy at Jone...

2024-04-25 18:33:59 ET Summary CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD...

2024-04-17 13:12:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generally, the idea of selling securities rankles the public’s nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more impor...

2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...

2024-04-16 14:25:11 ET Jones Trading has initiated Janux Therapeutics ( NASDAQ: JANX ) at buy citing the promise behind the technology of the company's two lead programs, both in phase 1 for various solid tumors.... Read the full article on Seeking Alpha For further deta...